Introduction
Fucoidan is the aggregate name for algal polysaccharides extracted from brown seaweeds. The structure of fucoidan consists of a heparin-like molecule with an α-1,3-backbone or a repeat unit consisting of disaccharides containing α-1,3-linked fucose and a α-1,4-linked fucose with branches attached at the C2 positions (Supplementary Scheme A, available at Carcinogenesis Online) (1, 2) . The biological activities of fucoidan have been examined and reported elsewhere (2, 3) ; in particular, the antiproliferation and anticancer/antitumor abilities of fucoidan have recently drawn considerable attention. The antitumor effect of fucoidan is considered to be mediated via interferon γ-activated NK cells and is due to the chemical's antiangiogenic potency (4, 5) . Fucoidan can induce apoptosis by activation of caspase 3 and downregulation of the Erk-mediated pathways (6) as well as by activation of caspase 8 and inhibition of the human breast cancer MCF-7 cells growth (7) . In addition, fucoidan inhibits invasion and angiogenesis by human fibrosarcoma cells via a repression of matrix metalloproteinase 2 and 9 activities (8) .
Breast cancer is defined by the National Cancer Institute (NIH, USA) as 'cancer that forms in tissues of the breast, usually the ducts (the tubes that carry milk to the nipples) and lobules (glands that make milk). It occurs in both men and women, although male breast cancer is rare.' Breast cancer is one of the most common malignant diseases in western women and metastases are the main cause of almost all cancer deaths (9,10). The major reason for morbidity and mortality in breast cancer patients is the evolution of metastatic breast tumors and >90% of breast cancer-related deaths are caused by metastasis (occur in regional lymph nodes, bones, the liver and the lungs) and not the primary tumors (11) . Breast cancer is a complicated disease and is classified into various subtypes, including estrogen receptor-positive, progesterone receptor-positive, human epidermal growth receptor 2-positive and triple-negative breast cancer (i.e. estrogen receptor (12, 13) . In recent years, the systemic treatment of breast cancer has tended to have moved more toward targeted therapy and combined therapy rather than non-specific cytotoxic chemotherapy or hormone therapy (12, 13) .
Recent studies have indicated that transforming growth factor β1 (TGFβ1) acts to induce tumor progression and metastasis during the late stages of breast carcinogenesis (14) (15) (16) . TGFβ can be described as a tumor promoter, one ability being the induction of the TGFβ-mediated epithelial to mesenchymal transition (EMT), a process that allows epithelial cells to separate from their neighbors and migrate to distant regions during development of or during metastasis (16, 17) . In terms of its activation mechanism, the TGFβ signaling pathway is initiated through a heteromeric complex of type I and type II transmembrane serine-threonine kinase receptors. After ligand binding, TGFβ receptor II (TGFRII) recruits and phosphorylates TGFRI. Subsequently, an active TGFRI directly phosphorylates Smads, namely Smad2 and Smad3 (18) . These activated R-Smads associate with Smad4, called a commonpartner Smad (Co-Smad), and the complex then translocates into the nucleus. After this translocation event, the complex interacts with DNAbinding factors, including the EMT-inducing factors such as Snail, Slug, Twist and so on in order to regulate responsive genes (19, 20) .
Multiple extracellular signals derived from growth factors and cytokines including TGFβ have been shown to trigger the EMT in an autocrine and/or paracrine manner (21, 22) . During the EMT, the morphological transition of epithelial cells into fibroblastoid-like or mesenchymal-like cells occurs and this results in the loss of epithelial markers such as E-cadherin and γ-catenin and the gain of mesenchymal markers such as N-cadherin and vimentin. This disruption/loss of cell-cell adhesion and downregulation of E-cadherin is a hallmark of the EMT program (21, 22) . The development of metastasis is considered to be the final phase of solid tumor progression and which results in the majority of cancer-related deaths for most cancer patients (23) .
In recent studies, it has been reported that the TGFR-mediated signaling pathway is regulated by ubiquitin-dependent proteasomal pathways (24) . Ubiquitin-mediated proteolysis controls the amount of short-lived proteins present in a cell, including signaling transducers and cell-cycle regulators; this degradation can result in receptor Abbreviations: DMEM, Dulbecco's modified Eagle's medium; EMT, epithelial to mesenchymal transition; MTT, 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide; TGFβ, transforming growth factor β; TGFR, TGFβ receptor; PBS, phosphate-buffered saline. downregulation and changes in gene expression (25) . In general, ubiquitination is composed of two steps. Initially, the target protein is recognized and ubiquitin molecules are attached. Subsequently, these polyubiquitinated proteins are disrupted by the 26S proteasome complex. Enzymes that participate in ubiquitination include ubiquitinactivation enzyme (E1), ubiquitin-conjugation enzyme (E2) and ubiquitin ligase enzyme (E3) (26) . The E3 ubiquitin ligases are the primary complex that is responsible for the recognition of specific target proteins. Interestingly, the evolution of cancer is associated with a deregulation of E3 ubiquitin ligases (27) . For example, a C2-WW-HECT-domain E3 ligase called Smad ubiquitination regulatory factor 2 (Smurf2) participates in modulating TGFβ-mediated signaling by targeting TGFR and Smad2 (28) . Therefore, the degradation of specific components in the TGFβ signaling pathways is probably to play important roles in influencing the TGFβ-induced EMT program during tumor progression.
We studied 4T1 and MDA-MB-231 breast cancer cells in vitro and found that fucoidan inhibits their proliferation and their colony formation ability. We also demonstrated that fucoidan inhibits tumorigenesis and metastasis to the lungs of 4T1-bearing mice in vivo. Using western blot analysis, we examined the expression of EMT-related biomarkers and transcriptional repressors; this was done in parallel with an examination of Smad-dependent proteins expression across the TGFβ signaling pathways. Initially, we found morphology changes in 4T1 and MDA-MB-231 cells after fucoidan treatment. Specifically, fucoidan seems to block metastasis progression by enhancing epithelial-specific markers and decreasing mesenchymal-specific markers. In parallel, we found that there was a reduction in the protein expression of phosphorylated Smad2/3 and Smad4 and a decrease in the levels of TGFRI and TGFRII in the studied breast cancer cells after treatment with fucoidan. Moreover, in order to investigate and understand the mechanism by which fucoidan reduces TGFRI and TGFRII in MDA-MB-231 cells, we demonstrated the direct involvement in this process of ubiquitin-proteasome-mediated degradation. This study explores in detail how fucoidan plays an important role in the disruption of TGFR protein expression via the TGFR/Smad/Snail, Slug and Twist/EMT axes; moreover, the findings further suggest that fucoidan might have potential as a therapeutic agent against breast cancer.
Materials and methods

Cell cultures
The MDA-MB-231 and MCF-7 human breast cancer cells and 4T1 mouse breast adenocarcinoma were obtained from the American Type Culture Collection (USA) and maintained in Dulbecco's modified Eagle's medium (DMEM) with 10% heat-inactivated fetal bovine serum, 200 mM l-glutamine and 1x non-essential amino acids. The cells were maintained in a 5% CO 2 atmosphere at 37°C in an incubator.
Reagents and antibodies
The fucoidan powder from Fucus vesiculosus is a commercial product and was purchased from Sigma Co. (USA) or Hi-Q oligo-fucoidan ® as gift from Hi-Q Marine Biotech International Ltd (Taiwan). It was dissolved in double-distilled H 2 O and stirred at 25°C for 30 min. The dissolved solution was filtered using 0.22 μm sterile filters (Millipore). The proteasome inhibitor, MG-132, was purchased from CalBiochem, EMD Biosciences. Antibodies against Smad4, p-Smad2/3, β-actin, TGFβRI, TGFβRII, γ-catenin, Twist, Lamin A/C, antirabbit IgG-horseradish peroxidase, antimouse IgG-horseradish peroxidase, antirat IgG-horseradish peroxidase antibodies (for immunoblotting) and protein A/G plus-agarose were obtained from Santa Cruz Biotechnology. E-cadherin and N-cadherin antibodies were obtained from BD Transduction Laboratories. Vimentin antibody was purchased from Thermo Scientific. Snail antibody was purchased from Abcam plc. Slug antibody was purchased from Cell Signaling Technology. Antiubiquitin antibody was purchased from GeneTex (USA).
Cell extracts and western blotting analysis
The breast cancer cells or other indicated cells were grown on 6 cm tissue culture plates and treated with fucoidan for the indicated times. The cells were then washed once with 1 ml ice-cold phosphate-buffered saline (PBS) containing 1% Na 3 VO 4 ; the cells were lysed using 40 μl lysis buffer. The protein concentration of the supernatant was then measured by Bradford protein assay (Bio-Rad) with bovine serum albumin as a standard. For western blotting analysis, total cell lysates, either from a breast cancer cells culture or from the tumors obtained from xenografts, were subjected to sodium dodecyl sulfatepolyacrylamide gel electrophoresis of western blotting as described (29) . The specific proteins tested for were visualized by the enhanced chemiluminescence western blotting system.
Nuclear protein extraction
All nuclear extraction procedures were performed on ice using ice-cold reagents. Cells were washed twice with cold PBS (with 1% Na 3 VO 4 ) and harvested by scraping into lysis buffer. They were then incubated for 15 min with occasional vortexing. After centrifugation at 13 000g, one cell pellet volume of 0.5% Nonidet P-40 was added to the nuclear pellet and incubated on ice for 15 min with vortexing. The nuclear proteins were isolated by centrifugation at 13 000g for 15 min and used for western blot analysis.
Cell viability assay (MTT assay)
Cells (1 x 10 4 cells per well) were seeded in triplicate on a 96-well plate and incubated overnight before treating with fucoidan (60-120 μg/ml) for 24-48 h. After incubation, 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) dye was added and the mixture was incubated for 2 h as described by Wu et al. (29) .
Colony formation assay
Breast cancer cells were plated at 3000 cells per well in six-well plates. The base agar layer was made by using 0.5% agar solution and 2× DMEM. The upper cell containing agar layer was made by mixing 2× DMEM with melted 0.33% agar solution. The plates were incubated at 37°C under 5% CO 2 for 21~28 days. After incubation, the cells were fixed in methanol for 10 min and stained with 10% Giemsa stain for 20 min at room temperature. After removing the dye by washing, the plates were photographed and the number of colonies present was counted by eye.
Migration and invasion assays
The migration activity of breast cancer cells was assessed by the Costar Transwell ® procedure. In brief, 1 x 10 4 cells per each well were seeded in the upper chamber in diluted 0.5% fetal bovine serum-DMEM and treated with fucoidan (100 μg/ml). The cells migration ability over 24 h was then assessed. For the breast cancer cells invasion assay, Transwell ® filters coated with an appropriate amount of Matrigel ® (Becton Dickinson Biosciences) were used. About 5 x 10 4 cells per each well were seeded in the upper chamber wells and incubated for 24 h. Cells that migrated through the basement membrane filter were fixed with 70% methanol for 10 min and stained with Liu stain. The lower face of the membrane was examined and the migrated cells were counted under a microscope.
Animals and fucoidan treatment
Female Balb/c strains of mice were obtained from the National Laboratory Animal Center of Taiwan. Mice aged 6-8 weeks were kept under a standard protocol approved by the institutional animal care of National Yang-Ming University. Each mouse was injected with 4T1 cells (2 x 10 5 cells per mouse) into the mammary fat pads. To examine the effect of fucoidan on tumor volume, the mice were randomly distributed into two groups and injected with either PBS (control group) or fucoidan (0.25 mg/mice, experimental group). The treatment period was 36 days and we recorded the body weight and tumor volume (V) (calculated by using the formula: V = length × width × thickness in mm 3 ) of each mouse three times each week. At the end of treatment, the liver, lung and tumors of the mice were surgically collected after killing. The whole lungs were excised and fixed in 10% formalin solution. The metastatic nodules (white spots) of the visible tumor lesions on lung surface were identified by color and appearance and counted under a dissecting microscope.
Immunoprecipitation of TGFR as part of the in vitro ubiquitination assay
To assess the ubiquitin regulation ability of fucoidan in MDA-MB-231 cells, the cells were pre-cultured in MG-132 (10 μM) for 30 min to inhibit proteasome activity and this was followed by treatment with or without fucoidan (100 μg/ ml) for 15 and 30 min. The cells were extracted with lysis buffer and then centrifuged at 13 000g for 10 min at 4°C. The cleared supernatants were prepared for immunoprecipitation. The cell lysates (~200 μg protein) were immunoprecipitated overnight at 4°C with various primary antibodies (1 μg) and protein A/G were added to the immunoprecipitates followed by incubation at 4°C for overnight. The beads were collected by centrifugation at 10 000g for 2 min and washed four times in PBS containing protease inhibitors and phosphatase inhibitors. The immunoprecipitation complex was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis, followed by immunoblotting with antiubiquitin antibody in order to detect polyubiquitinated TGFRII proteins. The results of the in vitro ubiquitination assay were visualized by an enhanced chemiluminescence western blotting system.
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Statistical analysis
All data are expressed as the mean ± standard error. Significant differences between two groups were determined by t-test analyses using Microsoft Excel. A P value of <0.05 was considered statistically significant.
Results
Fucoidan inhibits the proliferation of, the transforming capability of and colony formation by breast cancer cells
In order to test the response of 4T1 and MDA-MB-231 breast cancer cells to fucoidan, we initially examined the growth pattern of cancer cells when treated with fucoidan. Using a MTT assay, the effect of fucoidan on the growth of cancer cells for 24 and 48 h was examined and we found about a 30-40% inhibition of cell viability after 48 h of fucoidan treatment (at 90 and 120 μg/ml) compared with the control cells ( Figure 1A-1 and A-2) , although there was a less significant change in cell viability upon 24 h fucoidan treatment. Based on the above, 4T1 and MDA-MB-231 cells were treated with fucoidan at 90/120 μg/ml to better explore the compounds anticancer ability. Similar results were found in MTT assay of human breast cancer MCF-7 cells (data not shown). Moreover, in order to investigate whether fucoidan inhibits the transforming ability of these cell lines and to correlate this with tumor formation in vivo, we carried out soft agar colony formation assays and found that fucoidan inhibits colony formation of MDA-MB-231 cells by ~60% compared with the controls (Figure 1B) .
Fucoidan inhibits the tumorigenesis and metastasis of breast cancer to the lungs in vivo
Because we have demonstrated above that fucoidan suppresses certain properties of tumorigenesis in 4T1 and MDA-MB-231 cells in vitro, we used fucoidan to treat a 4T1 xenograft mice model in vivo. 4T1 cells were injected into the mammary fat pads of female Balb/c mice and the tumor growth rate was assessed over 36 days. We found that mice injected with fucoidan showed a marked reduction in tumor volume compared with the PBS control groups (Figure 2A and B) . Moreover, based on the high metastatic ability of 4T1 cells in mice (30) , we also investigated the number of metastatic tumor nodules present in the lungs of the 4T1-xenografted mice ( Figure 2C ). The multiplicity (average number) ( Figure 2D ) in the fucoidan-treated mice was obviously and significantly diminished compared with the PBS control group. These results show that fucoidan treatment suppresses the tumorigenesis and formation of lung metastases after injection of 4T1 cells into mice. 
Fucoidan affects EMT-relevant morphology changes and alters the expression of EMT-related markers and transcriptional repressors in breast cancer cells
It is known that >90% of breast cancer-related deaths are caused by metastasis, rather than by primary tumors (31) . Based on our above results, it would seem that fucoidan reduces the metastatic ability of breast cancer cells. During cancer spreading or metastasis, epithelial cells separate from their primary tumor lesions via the EMT and then migrate to distant organs; therefore, we investigated whether fucoidan is able to inhibit such metastasis-relevant properties. Fucoidan was used to treat 4T1 cells (Supplementary Figure S3A , available at Carcinogenesis Online, a time course study) and MDA-MB-231 cells (data not shown) for 72 h, and it could be noted that both types of cell changed their morphology. After fucoidan treatment, the cells lost their cell-cell non-adhesion (i.e. increase of cell-cell aggregation), their spindle-shaped and their fibroblast-like nature (mesenchymal-type morphology) and became cell-cell adherent, clustered and polarized (epithelial-type morphology). Similar results were found in MCF-7 cells (data not shown). Taking together, the results reveal that fucoidan inhibits or reverses the EMT in breast cancer cells in a species-independent manner.
In order to investigate the mechanism by which fucoidan brings about the EMT morphological changes in breast cancer cells, we examined the expression of epithelial markers and mesenchymal markers when the cells were treated with fucoidan. The expression of E-cadherin and N-cadherin in 4T1 cells ( Figure 3A ) and in MCF-7 cells (Supplementary Figure S3B , available at Carcinogenesis Online) was dose dependently increased and decreased, respectively, over 24 h by treatment with increasing amounts of fucoidan. The study of E-cadherin and N-cadherin expression was extended to MDA-MB-231 cells, which also showed that fucoidan dose dependently enhanced expression of E-cadherin and γ-catenin as well as a dose-dependent reduction in expression of N-cadherin and vimentin at 24 and 48 h ( Figure 3B-1 and B-2) . These results show that the expression of EMT markers in breast cancer cells, after treatment with fucoidan, occurs in both a time-dependent and dose-dependent manner. Thus, fucoidan is able to alter and modify the EMT process in various breast cancer cells at the molecular level in a species-independent manner.
Because transcriptional repressors such as Snail (Snail 1), Slug (Snail 2) and Twist are involved in triggering the EMT process via the suppression of E-cadherin (22) , the effect of fucoidan on the expression of transcriptional repressors in the breast cancer cells was explored. We found that fucoidan significantly decreases expression of Snail and Slug in 4T1 ( Figure 3C 
Fucoidan inhibits mobility (migration and invasion) of breast cancer cells as measured by Transwell
® assays It is known that the EMT occurs because of remodeling of epithelial cells and the alteration of the cell morphology into a mesenchymal type, which facilitates cell migration and invasion (22) . A Transwell ® Fig. 3 . Fucoidan alters EMT-related properties in breast cancer cells: morphological changes, biomarkers, some transcriptional factors, migration and invasion. (A and B) Dose-dependent studies on the effect of fucoidan on EMT-related biomarkers in several breast cancer cell lines. Cells (4 × 10 5 cells per well in 6 cm dish) were treated with various doses of fucoidan (between 60 and 120 μg/ml as indicated) for 24 or 48 h. After incubation, the whole cell lysates were collected and the expression of E-cadherin and N-cadherin was assessed by western blotting for 4T1 (3A) and MDA-MB-231 cells (3B-1 and B-2). One representative of three independent experiments is shown. (C) Fucoidan inhibits the expression of the EMT-related transcriptional factors Snail, Slug and Twist. Cells (4 × 10 5 cells per well in 6 cm dish) were treated with various doses of fucoidan (between 10 and 120 μg/ml as indicated) for 2 h; then, the expression of Snail and Slug in 4T1 cells (3C-1) was measured by western blotting. MDA-MB-231 cells (4 × 10 5 cells per well in 6 cm dish) were treated with various doses of fucoidan (60, 90 and 120 μg/ml); then, the expression of Twist (2 h) or Snail (24 h) was measured by western blotting (3C-2). β-actin was used as the internal control and the numbers below the β-actin row indicate the densitometric values normalized against the relative β-actin value. One representative of three independent experiments is shown. (D and E) Fucoidan inhibits the migration and invasion of MDA-MB-231 and 4T1 cells. Cells were seeded into the upper chamber wells, with 1 × 10 4 cells per well for the migration assay or 5 × 10 4 cells per well for the invasion assay and incubated with fucoidan (100 μg/ml) for 24 h. After 24 h, (3D) for the migration assay, the inserts were fixed with 70% methanol for 10 min, which was followed by staining with Liu stain. The numbers of cells that migrated were observed and counted using an Olympus IX70 inverted microscope and SPOT advanced digital imaging software. Statistically significant differences are shown compared with the control group difference (**P < 0.01). One representative of three independent experiments is shown. (3E) For the invasion assay, the inserts were fixed with 70% methanol for 10 min followed by staining with Liu stain. The numbers of cells that migrated were observed and counted using an Olympus IX70 inverted microscope and SPOT advanced digital imaging software. Statistically significant differences are shown compared with the control group difference (**P < 0.01). One representative of three independent experiments is shown.
assay was used to examine the migration and invasion abilities of breast cancer cells when treated with fucoidan in vitro and it was found that the migration capacity of MDA-MB-231 and 4T1 cells, when incubated with fucoidan for 24 h, was reduced by >30% and 50% compared with the control cells ( Figure 3D ). Similar results of fucoidan reduction of migration in MCF-7 cells were found (data not shown). In addition, the invasion efficiency of the fucoidan-treated MDA-MB-231 and 4T1cells was decreased by ~50% compared with the control cells ( Figure 3E ).
Fucoidan decreases TGFR-mediated Smad signaling pathway activity in breast cancer cells
The molecular network of TGFR, which regulates the EMT, has been investigated in previous studies (17) . Also, it has been reported that TGFR/Smad-dependent pathway molecules such as Smad2 and Smad3 have distinct roles in breast cancer-bone metastasis by MDA-MB-231 cells in female Balb-c nu/nu mice (32) . Here, we found that fucoidan decreases Smad2/3 phosphorylation, namely the expression level of phosphorylated Smad2/3 (p-Smad2/3), in 4T1 cells ( Figure 4A-1 Figure 4B ). We further found that as early as 3 h of fucoidan treatment, there was a decrease in Smad4 protein content in the nucleus and cytoplasm compartments compared with the control cells ( Figure 4C ). 5 cells per 10 cm dish) were treated with fucoidan (100 μg/ml) for 3 h. After treatment, the cytoplasmic proteins and nuclear proteins were carefully separated; the expression of Smad4 (H-552) in the cytoplasmic and nuclear lysates were detected by western blotting. In the studies (A), (B) and (C), β-actin was used as the internal control and the numbers below the β-actin row indicate the densitometric values normalized against the relative β-actin value. The experiment from each study is representative of three similar experiments. 5 cells per well in 6 cm dish) were treated with fucoidan (60, 80, 100 and 120 μg/ml) for 1 (5A-1) or 24 h (5A-2). This was followed by western blotting of the whole cell lysates to detect the expression of TGFβRI (V-22) and TGFβRII (C-16). The β-actin was used as the internal control and the numbers below the β-actin row indicate the densitometric values normalized against the relative β-actin value. This experiment is representative of three similar experiments. (B) Western blotting analysis reveals that treatment with the proteasome inhibitor MG-132 results in the recovery of TGFR protein levels after fucoidan-affected TGFR protein depletion. MDA-MB-231 cells (5 × 10 5 cells per well in 6 cm dish) were pre-treated with MG-132 (5 μM, dissolved in dimethyl sulfoxide) for 1 h, which was followed by additional treatment with fucoidan (100 μg/ml) for 30 min. After treatment, the expression of TGFRI (V-22) and TGFRII (C-16) was measured by western blotting. β-actin was used as the internal control and the numbers below the β-actin row indicate the densitometric values normalized against the relative β-actin value. This experiment is representative of three similar experiments. (C) Detection of ubiquitin (Ub) levels by immunoprecipitation of TGFRII in MDA-MB-231 cells (1 × 10 6 cells per well in 10 cm dish) that had been pre-treated with MG-132 (10 μM) for 30 min, followed by additional treatment with fucoidan (100 μg/ml) for 1 h. After incubation, the whole cell lysates were immunoprecipitated overnight at 4°C by anti-TGFRII antibody. The results showed the elevation of poly-Ub expression in the presence of fucoidan; Ub and TGFRII levels were measured by western blotting. This experiment is representative of three similar experiments.
Fucoidan decrease breast cancer TGFR by ubiquitin-dependent
Fucoidan reduces expression of the TGFRs (TGFRI and TGFRII) in breast cancer cells via accelerated ubiquitin-dependent proteasome-mediated degradation
Moreover, we directly examined the effect of fucoidan on TGFRI and TGFRII proteins expression in such cells. Western blotting analysis showed that treatment of the breast cancer cells with fucoidan for 1 h resulted in a dose dependent and rapid reduction in the protein expression of TGFRI and TGFRII using 4T1 and MDA-MB-231 cells compared with control cells (Figure 5A-1) . This was also found to be true after 24 h when MDA-MB-231 cells were fucoidan-treated ( Figure 5A-2) . One possible mechanism by which the fucoidaninduced decrease in TGFRI and TGFRII protein might occur, as has been previously reported, is ubiquitin-dependent proteasomemediated degradation. As expected, it was found that cells incubated with fucoidan showed a 30% decrease in the protein levels of TGFRI ( Figure 5B , upper panel, sample 3 versus sample 4) and TGFRII ( Figure 5B , lower panel, sample 3 versus sample 4). We also found that the addition of MG-132, a proteasome inhibitor, to the cells was able to lower the fucoidan-induced degradation of TGFRI ( Figure 5B In order to further explore the mechanism of fucoidan-induced decrease in the levels of the TGFR proteins, an in vitro ubiquitination activity assay was conducted against the ubiquitin proteins to examine the role and involvement of ubiquitin (ubiquitination) in fucoidan-mediated proteasome degradation of the TGFR proteins in MDA-MB-231 cells. The cells were pre-incubated with MG-132 and then treated with fucoidan, followed by incubation of the whole cell lysates with anti-TGFRs antibodies. The immunoprecipitated proteins were then assessed using antiubiquitin antibody. As shown in Figure 5C , we found that the degenerated TGFRII protein, but not the degenerated TGFRI protein (data not shown), could be detected with antiubiquitin antibody, indicating that TGFRII shows a higher level of ubiquitination than TGFRI during the fucoidan-induced decrease in TGFR proteins. Specifically, we demonstrated that the intensity of the smeared bands of degenerated TGFRII protein in the fucoidan-treated cells was stronger than the control cells ( Figure 5C ). Taken together, these results indicate that the smeared bands consisted of polyubiquitinated TGFRII protein and we are the first to demonstrate that ubiquitin-proteasome pathways are involved in the fucoidan-mediated and fucoidan-enhanced TGFR degradation in MDA-MB-231 breast cancer cells.
Discussion
In our cell culture studies, we selected estrogen receptor-negative and progesterone receptor-negative human breast adenocarcinoma MDA-MB-231 cells, which have been used and reported to form tumors in athymic mice (33) . 4T1, the Balb/c-derived mouse mammary carcinoma, as an excellent mice model of breast cancer is highly similar to human breast cancer in many tumor characteristics (34) . Additionally, 4T1 cells have micro-metastatic properties and can be detected at very early stages of growth; this allowed us to quantitatively monitor the effect of fucoidan on metastasis development. We demonstrated that fucoidan reduces the proliferation, transforming capability and colony formation ability of 4T1 and MDA-MB-231 breast cancer cells in vitro. We further demonstrated that fucoidan effectively inhibits tumorigenesis and reduces tumor volume in vivo as well as fucoidan reduces the metastasis of lung tissue in 4T1-xenografted mice.
The recent findings have demonstrated that TGFβ-mediated signal transductions in mammary tumors enhances lung metastatic dissemination (19, 35) . In brief, abrogating the TGFβ signaling pathways either by overexpressing a kinase defective, dominantnegative mutant form of the TGFRI or by reducing the expression of the Smad4 transcription factor is able to blunt the ability of cancer cells to metastasize to the lungs from established primary tumors. Indeed our results indicated that active TGFβ-mediated signaling in primary tumors enhances lung metastases, but that fucoidan treatment reduced and blocked the metastatic property in 4T1-bearing mice. Our present findings are also compatible with a previous report indicating that both single and repeated administration of fucoidan has antitumor and antimetastatic effects on transplanted murine LLC1 using a C57BL/6 mice model (36) .
The EMT has been shown to be closely related to the occurrence of tumor metastasis (37) . It has been reported that fucoidan derived from F.vesiculosus strongly blocks MDA-MB-231 cell adhesion to platelets (38) , though the mechanism by which fucoidan blocks metastasis has not been reported and studied in detail. We found that EMT-relevant cell morphology (phenotype) of fucoidan-treated 4T1, MDA-MB-231 and MCF-7 cancer cells change from a mesenchymal type to an epithelial type, which occurred in a concentration-dependent manner as well as in a cell-independent and species-independent fashion. It has also been reported that the forced expression of E-cadherin suppresses cancer metastasis, and an E-cadherin mutation in a tumor decreases cellular adhesion and increases cellular motility, invasion and metastasis (17, 39) . In this study, we demonstrated that fucoidan effectively upregulates the expression of EMT-associated proteins E-cadherin and γ-catenin, but downregulates the expression of N-cadherin and vimentin, all in a dose-dependent manner. The EMT process is closely associated with multiple membrane receptors and their related signaling pathways, all of which lead to tumor metastasis (17, 37) . During late tumor outgrowth, TGFβ acts as a tumor promoter and is a switch that moves the cell toward malignant progression (40) . Additionally, intense TGFβ staining has also been found to be positively correlated with EMT expression and metastasis in breast cancer (41) ; hence, TGFβ is considered a major inducer of EMT in breast cancer at a late stage. The important role of the TGFRmediating signaling molecule Smad2 in potentiating the EMT and EMT-related genes in enhancing skin cancer aggressiveness has been elucidated in early studies (42) . For the first time in this study, we examined the inhibitory effects of fucoidan on TGFR-induced EMT in human breast cancer cells (MDA-MB-231 and MCF-7) and murine breast cancer cells (4T1). We demonstrated that the multiple inhibitory effects of fucoidan on TGFβ/TGFR-mediated signalings, which include inhibition of TGFR expression, reduction of Smad2 and Smad3 phosphorylation and decrease of the Smad4 proteins translocation into the nuclear compartment. Moreover, we found that the EMT-related transcriptional repressors, Snail, Slug and Twist, were differentially reduced when cells were treated with fucoidan. This suggests that these transcriptional repressors are the upstream regulators of E-cadherin in the fucoidan-mediated EMT.
It has been proposed that dysregulation of TGFRI and/or TGFRII signalings would lead to cancer progression (17, 20) . Here, we found that fucoidan treatment of cancer cells reduces the protein levels of both TGFRI and TGFRII as early as 1 h and in a concentrationdependent manner. The fucoidan-induced TGFRI and TGFRII proteins degradation over a short period seems to be via a proteasomedependent processing rather than the involvement of transcriptional regulation. It has been reported that ubiquitination is important to the degradation of TGFβ-mediated signaling molecules, Smad1 and Smad2 (28, 43, 44) . In this study, we are the first to demonstrate that fucoidan-induced reduction in TGFRI and TGFRII proteins is blocked and reversed by the addition of a proteasome inhibitor, MG-132. Using this drug, it was possible to show that there was fucoidan regulation of protein levels of TGFRI and TGFRII and that occurred via a proteasome-mediated degradation pathway. Furthermore, we also found that ubiquitination activity against TGFRII but not TGFRI in MDA-MB-231 cells increased under fucoidan treatment. Our results suggest that fucoidan-induced TGFR degradation is probably to occur via an acceleration of ubiquitin-proteasome ability in breast cancer cells, which is similar to previous reports (24, 25) . Taking these results together, it is revealed that one of the mechanisms by which fucoidan reverses the EMT in the tested breast cancer cells is probably due to a decreased activation of the TGFR/Smad-dependent pathways and related signaling molecules. Moreover, fucoidan induces the changes in TGFβ-mediated EMT in breast cancer cells and these inhibited the growth and metastatic proliferation of tumor cells in 4T1 xenograft female Balb/c mice. Because the TGFβ/TGFR signal transduction pathways are regulated at multiple levels by ubiquitin-mediated targeting (24) and proteasomal degradation (45), we plan to further investigate whether the E3 ubiquitin ligases such as Smurf2, Smad7 and the Smurf2/Smad7 complex, which have been found to be associated with TGFR (28, 43) , are involved in the fucoidan regulation of TGFR degradation.
In summary, our in vivo results demonstrate that fucoidan significantly reduces tumor volume and the number of metastatic lung nodules in the 4T1 xenograft model. In order to dissect the mechanisms involved in the reduction by fucoidan of tumor growth in 4T1-bearing mice, we further demonstrated that fucoidan suppresses in vitro cells proliferation, colony formation, expression of EMT biomarkers and blocks cell migration and cell invasion, all of which are relevant to tumorigenesis in the breast cancer cells. In terms of TGFR functions, fucoidan inhibits the TGFR-mediated Smad pathways and blocks the ubiquitin-dependent proteasome-mediated degradation pathway of TGFRII at least. Finally, by pinpointing the role of ubiquitination and other relevant factors in the TGFβ/TGFR-mediated signal transduction pathways of cancer cells, we plan to identify novel therapeutic targets that ought to help to design new cancer treatments as some researchers proposed (45) . Our current findings indicate that fucoidan has potential as a therapeutic intervention for controlling breast cancer or other cancers and that manipulation of the proteosomal ubiquitin-dependent degradation of proteins in relation to the TGFR/Smad/Snail, Slug, Twist/EMT axes ought to be a beneficial strategy for cancer patients.
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